How Dei BioPharma’s mRNA platform will boost quick disease outbreak response & cut external supply dependable.

In a bold move to innovate African solutions compiled by African pharma makers and achieve health sovereignty, the Uganda based Dei Biopharma through the latest projects on vaccines production will according to experts will remove the long term barriers to Africa’s true health independence, coupled with registration of patent rights for African science. 

In a recent International public health conference held in Durban South Africa, Dr. Matthias Magoola, founder of Dei BioPharma Uganda, captured both the promise and the pain of this struggle.

In his keynote address, he unveiled two landmark innovations patented mRNA vaccines for Ebola and Mpox, developed and owned entirely in Africa.

“This patent represents a breakthrough in the continent’s pursuit of scientific and economic independence. It shows that Africa can invent, protect, and advance world-class biomedical technologies. We no longer wait for solutions, we create them” he said

Built on messenger RNA technology, the vaccines encode viral glycoproteins in lipid nanoparticles. Unlike traditional viral-vector vaccines, they don’t require live viruses, making them safer and faster to produce.

According to Dr Magoola, Dei BioPharma’s mRNA platform could drastically reduce the time needed to respond to disease outbreaks while cutting dependence on external suppliers.

He also revealed that his patented biotechnology could reduce the cost of cancer and diabetes treatments by up to 95%, making lifesaving drugs affordable for millions of Africans.

“More than 90% of patients in Africa cannot afford these biological medicines,” he explained. “Our research is designed to change that reality.” he said

Dr. Magiola making his speech during a recent health conference 

He appealed to the Africa Centres for Disease Control and Prevention (Africa CDC) to empower the African Medicines Agency (AMA) to independently regulate and approve locally made drugs.

“Without empowering AMA, our science will always be judged abroad. I work directly with the US FDA because there’s no viable alternative in Africa. The whole process here is long and riddled with doubt — as if nothing good can come from Africa. That must change if we are to become truly health independent” he aid

The urgency for African-led innovation is underscored by shrinking global support.

According to Africa CDC, international health aid to Africa has dropped by 70% between 2021 and 2025.